Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medix Biochemica's PROM (premature rupture of foetal membranes) test:

This article was originally published in Clinica

Executive Summary

Medix Biochemica's Actim PROM test is designed to rapidly detect the premature rupture of foetal membranes (PROM). The test has been marketed outside the US since 1995, and it was the first commercial test to recognise a protein highly specific for amniotic fluid, claimed the Kauniainen, Finland-based firm. This makes it less susceptible to common interfering factors that cause possible false positive or false negative results in other test methods, the company said. Last year, the firm won the first round in its legal wrangle with US company N-Dia concerning the infringement of patents related to diagnostic methods and test kits for detecting PROM (see Clinica No 1208 p 13).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel